SmartNuclide

News

Focus on the development and application of innovative diagnostic and therapeutic radiopharmaceuticals

AnnouncementSocial Media

Smart Nuclide Announces FDA Clearance of IND for the First Radioactive Imaging Agent Targeting PD-L105/31/2022

Suzhou, China, April 13, 2022 – Suzhou Smart Nucl […]

Smart Nuclide Announces the License Agreement with Hober Biotech AB For an Innovative HER2 Radioactive Imaging Agent01/31/2022

Suzhou, China and Stockholm, Sweden, January 12, 2022 & […]